tldrdailynews.com logo

Weight-loss jabs sharpen a class divide among middle-aged women

1 min read
Source: The Times
Weight-loss jabs sharpen a class divide among middle-aged women
Photo: The Times
TL;DR

New Health Foundation data shows middle-class women aged 30–50 are the dominant private-prescription users of weight‑loss injections like Ozempic and Mounjaro, prompting debate over affordability, ethics, and long-term health effects as researchers highlight side effects and a growing class divide in obesity treatment.

Topics:healthlife-and-style#glp-1#health-inequality#life-and-style#middle-class#ozempic#weight-loss
Share this article
  1. The big fat jab divide: why middle-class women are buying them  The Times
  2. Middle-class women aged 30-50 are main buyers of weight-loss drugs  The Times
  3. Women and middle classes dominate weight loss jab take-up  Sky News
  4. The people most likely to use weight loss jabs, according to new research  The Independent
  5. GLP-1 rollout could widen health inequalities, warns Health Foundation  Healthcare Leader

Want the full story? Read the original reporting

Read on The Times